Navigation Links
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
Date:3/25/2009

pital and other healthcare institutions in North America.

"This agreement highlights Galderma's commitment to the future of dermatology. Aganocide compounds have the potential to bring about significant progress in the treatment of skin diseases which affect millions of patients, without adding to the growing problem of antibiotic resistance," said Humberto C. Antunes, Chief Executive Officer of Galderma. "Galderma is glad to be working with NovaBay in this important and very promising endeavor."

"We are very pleased to have entered into this collaboration with Galderma, the world-leader in dermatology. We believe that Galderma's demonstrated development, regulatory and marketing capabilities, backed by its unrivaled reputation and track record of success, will enable NovaBay to benefit from accelerated development timelines and global commercial expertise," said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay. "Like our alliance with Alcon in the ophthalmic, otic and sinus fields, this agreement represents another major validation of the potential for our novel Aganocide products in treating infections caused by a wide range of bacteria, viruses and fungi."

The company's collaborations with Alcon and Galderma provide significant future revenue-generating potential for NovaBay, with favorable economic-sharing for its unique, differentiated products that address large, global dermatological and ophthalmic markets.

Conference Call

NovaBay will hold a conference call today, March 25, 2009 at 11:00 a.m. ET, to discuss its Galderma collaboration. The conference call will be simultaneously web cast on NovaBay's web site.

    Conference call details:
    Date:    Wednesday, March 25, 2009
    Time:    11:00 a.m. ET
    Dial-in (U.S.):   888-396-2384
    Dial-in (International): 617-847-8711
    Web cast:  
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
2. Galderma Completes Acquisition of CollaGenex
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
6. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
7. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
8. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
9. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
10. Neogen Acquires Kane Enterprises
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Launched by the ... in December 2011, ,SARAH, - the French ... versus sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled ... SARAH, a large French study of patients ... HCC) has completed patient enrolment, exceeding its 400-patient target, ...
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Halozyme Therapeutics, ... the Barclays 2015 Global Healthcare Conference in Miami, ... ET/10:05 a.m. PT. David A. Ramsay , Chief Financial ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... of the "Gene Therapy Market, 2015 - 2025" ... "Gene Therapy Market, 2015-2025" report provides an extensive study ... of research has been carried out in this field ... approved therapies (four available in Asian markets; one approved ...
(Date:3/3/2015)... March 03, 2015 BlueInGreen ... to their international sales network. The business venture ... technology to Canada’s Atlantic Provinces, exclusively through Resource ... as one of Canada’s premiere manufacturing representative firms, ... the municipal water and wastewater markets. More information ...
Breaking Biology Technology:Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2
... 19 ,Arpida Ltd (SWX: ARPN) was invited to ... new antimicrobial agents at the 47th annual,Interscience Conference ... is a major scientific conference where thousands of,scientists ... to discuss the,latest developments in the field of ...
... MannKind,Corporation (Nasdaq: MNKD ), focused on discovering, developing ... it,will present at the UBS Global Life Sciences Conference ... Grand Hyatt Hotel in New York, NY. Interested ... cast of the,presentation in the Investor Relations section of ...
... EMERYVILLE, Calif., Sept. 18 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the UBS Global Life Sciences conference on ... parties may access a live webcast of the,presentation ... recommended that listeners log on 15 minutes early ...
Cached Biology Technology:Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... and unstable angina patients placed on beta-blocker therapy corresponds ... study by researchers at Washington University School of Medicine ... in Kansas City. The study appears in the September ... Medical Association. , "In our investigation of acute coronary ...
... understand extreme sea creaturesExtraordinary creatures who inhabit extreme underwater ... three-year project. These deep-sea communities could reveal an evolutionary ... give us clues to how life could exist onother ... - incredibly hot environments in the deep sea - ...
... developed virus that introduces a blood pressure-lowering gene into cells ... levels for four months promises to take gene therapy for ... Baylor College of Medicine in a report released online in ... blood pressure is one of the leading causes of death ...
Cached Biology News:Survival of heart patients on beta-blockers varies greatly with genetic variation 2Survival of heart patients on beta-blockers varies greatly with genetic variation 3Survival of heart patients on beta-blockers varies greatly with genetic variation 4Gene therapy to lower blood pressure just enough 2
... portable, easy-to-use and makes identifying your samples more ... to use Labels withstand extreme lab ... Time/Date stamp Laboratory symbols ... Serialization feature makes you more efficient ...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
recombination at attR1 and attR2 sites...
Biology Products: